{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6o3t0LDA","lastupdate":"2020-10-01T00:00:00.000Z","update_date":"2020-10-01T00:00:00.000Z","lastModified":"Sep 7, 2024","active":1,"confidence_score":100,"confidence_score_reason":"markets","urlname":"ioptima","minimal_profile":null,"status":"Acquired","fullstatus":"Acquired by Chengdu Kanghong Pharmaceutical Group on Sep, 2018","acquired":1,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$H1wowUC40Qeej0FpZ0qzhpPbY8yAVp0DaGt9WiGu5chRMTsjlN6grl","name":"IOPtima","oneliner":"Surgical Ophthalmic Laser Devices and Accessories","registrar":"513264424","website":"https://www.ioptima.com","careerspage":"","founded_month":1,"founded_year":2005,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/IOPtima","youtube":"https://www.youtube.com/user/IOPtimaVideos","facebook":"","linkedin":"https://www.linkedin.com/company/5022298","instagram":""},"social":["https://www.youtube.com/user/IOPtimaVideos","https://twitter.com/IOPtima","https://www.linkedin.com/company/5022298"],"flattenedsociallinks":"https://www.youtube.com/user/IOPtimaVideos|https://twitter.com/IOPtima|https://www.linkedin.com/company/5022298","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"1-10","employees_exact":8,"patent":1,"raised":7200000,"stage":"Acquired","public_stage":"Acquired","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"IOPtima is a rapidly growing company focused on developing minimally invasive and innovative surgical ophthalmic devices. Its flagship product, the IOPtimate, is a surgical system for the treatment of glaucoma that utilizes CO2 laser technology to significantly reduce internal eye pressure without penetrating the eye. The company also offers a line of patented eye drops to treat ocular surface diseases.\r\n\r\nIOPtima is a Kanghong Pharmaceutical company.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+972723922081","country":null,"address":{"israeli":[{"id":"c53917bc-a619-4b23-9cfd-be87871cc933","city":"Caesarea","type":null,"address":"Leshem St 10, Caesarea, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"bed068a3-bd51-4090-a92f-1c0591498ad7","date":"Sep 27, 2018","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3746606,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"investment, acquisition","company":"Chengdu Kanghong Pharma Group Co. Ltd.","layoffs":null,"summary":"Chengdu Kanghong Pharma Group has acquired a 41% stake in Tel Aviv-based medical technology company IOPtima for $17.2 million, solidifying its ownership. This investment brings Chengdu Kanghong Pharmas stake in IOPtima to 60%, as they had previously acquired a 19% stake in 2017. Chengdu Kanghong Pharma plans to acquire the remaining stake in two additional stages. IOPtima develops minimally invasive devices for eye surgeries, with its flagship product, IOPtimate, being a laser-based surgical system for the treatment of Glaucoma. The company has regulatory approval for marketing the system in several territories.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Chengdu Kanghong Pharma","IOPtima","medical technology","eye surgery","Glaucoma"],"date_of_event":"2018-09-27","valuation_amount":"$42 million","impact_on_company":"growth-positive","investment_amount":"$17.2 million","structured_issues":["Investment","Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PDD3Q8RpnQTXzVAdr1oql101bgJNbGD223ZNgTo8Q8ozROuxPho3ve","news_summary":"Chengdu Kanghong Pharma Solidifies Ownership of Israeli Medical Device Company","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4f83741f-c220-4ad3-8553-77601b307b0e","date":"Nov 21, 2017","link":"https://en.globes.co.il/en/article-chengdu-kanghong-pharma-buys-israels-ioptima-1001212714","source":"en.globes.co.il","visible":1,"analysis":{"tags":"acquisition","company":"BioLight Israeli Life Sciences Investments Ltd.","layoffs":null,"summary":"BioLight Israeli Life Sciences Investments Ltd. has completed the sale of its subsidiary, IOPtima, to Chengdu Kanghong Pharmaceutical Group. The acquisition will generate $23-27.3 million in cash flow for BioLight. Chengdu Kanghong will also become a distributor of IOPtimas products in China. BioLights share price increased by over 10% as a result of the deal.","partners":null,"customers":null,"investors":"Chengdu Kanghong Pharmaceutical Group","confidence":9,"key_topics":["ophthalmology products","IOPtima","Chengdu Kanghong Pharmaceutical Group","cash flow","market cap"],"date_of_event":"November 21, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"k4ZQxjuDHVmy4jIeMZtvKc9tqYbtUASDwz4sheYFH52yyC2tjGJd5r","news_summary":"Chengdu Kanghong Pharma buys Israel's IOPtima for $56m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"99ca9aad-3f4a-4fbb-a25f-7324892725d8","date":"Oct 2, 2017","link":"https://www.healio.com/ophthalmology/cornea-external-disease/news/online/%7B713839b3-9fa4-4bca-8741-fa6820452d1b%7D/ioptima-launches-lipitear-phospholipid-microemulsion","source":"www.healio.com","visible":1,"analysis":{"tags":"ophthalmology, ocular surface disorder","company":"IOPtima","layoffs":null,"summary":"IOPtima has launched Lipitear, a phospholipid-based microemulsion that helps restore the ocular surface and enhances corneal re-epithelization after surgery. It reduces symptoms of ocular surface disorder and prevents tear evaporation. The device is currently marketed in Europe under a CE mark but is not yet registered in the United States.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Lipitear","ocular surface disorder","dry eye","corneal re-epithelization","CE mark"],"date_of_event":"October 02, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Tw824vNEk55gf6g3uYmjnvJWPHi9BlzozTQvPnl94jj628Bx7hKarP","news_summary":"IOPtima launches Lipitear phospholipid microemulsion","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bc0e490a-2411-43fd-a3bf-14510813e442","date":"Jul 12, 2017","link":"https://www.healio.com/ophthalmology/oculoplastics/news/online/%7Bfb4743dc-d544-4352-904e-8ff290c6952a%7D/ioptima-launches-ilid-co2-laser-kit-for-blepharoplasty","source":"www.healio.com","visible":1,"analysis":{"tags":"medical technology","company":"IOPtima","layoffs":null,"summary":"IOPtima has launched the iLid CO2 laser kit, designed for oculoplastic surgeons to perform CO2 laser-assisted blepharoplasty. The kit offers several benefits, including reduced bruising, swelling, and pain, shorter recovery period, and better cosmetic results. It is based on the IOPtiMate system used for CO2 laser-assisted sclerotomy surgery for glaucoma.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["iLid CO2 laser kit","oculoplastic surgeons","CO2 laser-assisted blepharoplasty","reduced bruising and swelling","better cosmetic results"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ffAwaWpaz006ruMjjRJVe5FTXdKwK6pU0u7geKnYg7CIsVieesnHwz","news_summary":"IOPtima launches iLid CO2 laser kit for blepharoplasty","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d4d9ac02-640f-4485-b205-ed05ea343bbf","date":"Apr 19, 2017","link":"http://www.globes.co.il/en/article-biolight-to-sell-ioptima-to-chinese-co-1001185419","source":"www.globes.co.il","visible":1,"analysis":{"tags":"Acquisition, Investment","company":"BioLight","layoffs":"N/A","summary":"BioLight Israeli Life Sciences Investments Ltd. has signed a memorandum of understanding for the sale of its leading product, the only one directly generating revenue for the company, to a Chinese company, Chengdu Kanghong Pharma. Chengdu Kanghong Pharma will invest $7 million in IOPtima for 19% of that companys shares at a $30 million company value. The Chinese company will receive an exclusive license to market IOPtimas product in China. After six months, the Chinese company will acquire additional shares in IOPtima from the existing shareholders, including BioLight, thereby increasing Chengdu Kanghong Pharmas IOPtima stake to 60%, for $17.2 million, reflected a $42 million company value.","partners":"Chengdu Kanghong Pharma","customers":"N/A","investors":"Chengdu Kanghong Pharma","confidence":9,"key_topics":["Stake Sale","Investment","Acquisition","Glaucoma Treatment","Revenue Generation"],"date_of_event":"April 19, 2017","valuation_amount":"$30-56 million","impact_on_company":"growth-positive","investment_amount":"$7 million","structured_issues":["Acquisition","Investment"],"acquisition_amount":"$17.2 million","structuredIssuesShow":"#Acquisition  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"EruHqS9vzdtY7pIsWNvUrloWOZgZ2v0jNVKM9eKE5dZfEZHUNsGNzU","news_summary":"BioLight to sell IOPtima to Chinese co","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2ffb2e50-f578-48a4-9df4-81cf16ccb27b","date":"Dec 21, 2015","link":"http://www.prnewswire.com/news-releases/bio-lights-ioptimatetm-system-receives-regulatory-approval-in-canada-563113391.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Product Approval, Expansion","company":"Bio Light Israeli Life Sciences Investments Ltd.","layoffs":"Not mentioned","summary":"Bio Light Israeli Life Sciences Investments Ltd. has received approval from the Canadian Medical Devices Bureau for its IOPtiMate system for the treatment of glaucoma. This approval allows the company to commercialize the surgical system in Canada. The IOPtiMate system enables a non-penetrating, CO2 laser-assisted procedure known as CLASS to reduce elevated intraocular pressure. The company is primarily marketing the system to leading physicians and medical centers in Asia and Europe. The company has also signed a joint-financing agreement with two Asia-based venture capital firms to support the global commercialization of the IOPtiMate system.","partners":"Two Asia-based venture capital firms","customers":"Physicians and medical centers in Asia and Europe","investors":["Mr. Israel Makov","Mr. Dilip Shanghvi","Mr. Dan Oren","Rock-One"],"confidence":9,"key_topics":["Glaucoma Treatment","Canadian Approval","Commercialization","Investment","Expansion"],"date_of_event":"December 21, 2015","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1sbUJiD8dvBe7MiaFKUoJqB4vEiVvUpPOwMSQ5KHsoGRoJqxLumoVY","news_summary":"Bio Light's IOPtiMate[TM] System Receives Regulatory Approval in Canada","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c0063dba-61ce-4a9d-ac23-460b6b14cd19","date":"Mar 11, 2014","link":"http://www.asianscientist.com/2014/03/pharma/biolight-china-glaucoma-2014/","source":"www.asianscientist.com","visible":1,"analysis":{"tags":"investment","company":"BioLight","layoffs":null,"summary":"BioLight, an Israeli investment group, has raised $5.5 million in equity financing. The company plans to enter the Chinese glaucoma market, which is the largest in the world. BioLights subsidiary, IOPtima Ltd., has received approval from the China Food and Drug Administration to market and sell the IOPtiMate™ system, a surgical device for glaucoma treatment. The financing and approval will support the expansion of marketing and sales activities for the IOPtiMate™ system, as well as the advancement of other products into clinical trials.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["BioLight","Chinese Glaucoma Market","equity financing","IOPtiMate™ system","clinical trials"],"date_of_event":"March 11, 2014","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$5.5 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"DaKYISoPDNZLzkO8y81b76pYWEGGD2Ga3w3S3xYOKmz3r74EtrTeoc","news_summary":"BioLight Eyes Chinese Glaucoma Market, Raises US$5.5 Million - Asian Scientist Magazine","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5328265b-01d8-4777-a7d9-c9f767479bbf","date":"Nov 16, 2009","link":"https://www.bioopticsworld.com/articles/2009/11/ioptima-receives-europea-patent-approval-for-laser-system-for-treatment-of-glaucoma.html","source":"www.bioopticsworld.com","visible":1,"analysis":{"tags":"security","company":"www.bioopticsworld.com","layoffs":null,"summary":"The article discusses the use of a security service by www.bioopticsworld.com to protect against online attacks.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["security"],"date_of_event":"07/05/2023","valuation_amount":null,"impact_on_company":"N/A","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"none;"},"sentiment":"N/A","analysisId":"k50vc6cQTd3ulH7XWsNzAMGP6IkL3HOXhs1F0XY8hV62HjivXxjgYp","news_summary":"https://www.bioopticsworld.com/articles/2009/11/ioptima-receives-europea-patent-approval-for-laser-system-for-treatment-of-glaucoma.html","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"292e0478-09a2-4767-a2f5-2342f3bdbd84","date":"Sep 21, 2007","link":"https://www.israel21c.org/israels-ioptima-shines-a-light-at-the-end-of-the-glaucoma-tunnel/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"glaucoma treatment","company":"IOPtima","layoffs":null,"summary":"Israeli startup IOPtima has developed a breakthrough treatment for glaucoma using a carbon dioxide laser technology. The companys OT134 device allows eye surgeons to easily operate on glaucoma patients, making the procedure simpler and safer. The treatment has been successful in pre-clinical trials and has garnered interest from eye surgeons worldwide. IOPtimas technology offers better efficacy and safety advantages compared to traditional drug and surgery therapies for glaucoma. The treatment has the potential to significantly improve glaucoma surgery outcomes and reduce complications. It also has the potential to open up possibilities for glaucoma surgery in developing countries where prolonged treatments with eye drops are not feasible. The company aims to make glaucoma surgery fast, convenient, effective, and safe.","partners":null,"customers":null,"investors":"Bio-Light Life Science Investments","confidence":8,"key_topics":["glaucoma treatment","laser technology","eye surgery","medical device","clinical trials"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mPnbfMTWkcfE2TeeE9pilT8RCNoAAuwI1Q0q2pRNKJNBkSXrXal9oF","news_summary":"Israel's IOPtima shines a light at the end of the glaucoma tunnel","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":9,"techcommunityinvolvement":null,"mediagallery":[{"id":"c943195c-9eee-47b6-80c9-f1905b464c07","timestamp":"2020-09-23 07:20:22.000000","resources_type":2,"resources_title":"","resources_file_name":"2wkoBBgfucY","alt":"","imageurl":"https://img.youtube.com/vi/2wkoBBgfucY/0.jpg","url":"http://youtu.be/2wkoBBgfucY"},{"id":"91494231-9454-4dd1-beb6-ed71a51c4eaf","timestamp":"2020-09-23 07:20:12.000000","resources_type":2,"resources_title":"","resources_file_name":"EICh2KKBECQ","alt":"","imageurl":"https://img.youtube.com/vi/EICh2KKBECQ/0.jpg","url":"http://youtu.be/EICh2KKBECQ"}],"tags":["medical-devices","eye-diseases","minimally-invasive","surgery","lasers","glaucoma","ophthalmology","hospitals","pharma-companies","clinics","healthcare-providers","medical-technologies","optronics"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuXyawKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LvQ9JYJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":["Lipitear","iScan","iLid","IOPtimate","Flapper","LipiTear","Fabilas"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":3,"lastfunding":"$7.2M","totalrounds":1,"fundingstage":"Acquired","totalfunding":"$7.2M","publicinvestors":3,"lastpublicfunding":7200000,"totalpublicrounds":1,"totalpublicfunding":7200000},"team":[{"name":"Ronen Castro","email":"ronen@ioptima.co.il","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoJXpgIIIDA","bounced":false,"claimed":1,"founder":0,"urlname":"ronen-castro-4","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgjozBigoM","position":"CEO","last_name":"Castro","claimtoken":"abffd97d5867c46860a5a0ed9263016d15315097cf0a040157dff5574326d83a","first_name":"Ronen","picturekey":"$xROqOjKMGgcbQp5dKIQeIHuS3g2sRtolPjnac7uSYUPXJ1a3npFmzD","claimeddate":"2018-08-15","linkedinurl":"https://www.linkedin.com/in/ronencastro","unsubscribed":false,"is_activeuser":1,"additionalemail":"ronencastro@gmail.com","claimedemaildate":"2018-08-15 09:29:11.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$xROqOjKMGgcbQp5dKIQeIHuS3g2sRtolPjnac7uSYUPXJ1a3npFmzD","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Eran Kaplan","email":"eran@ioptima.co.il","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoIfrvuoLDA","bounced":false,"claimed":0,"founder":0,"urlname":"eran-kaplan-2","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgke_XjQoM","position":"VP R&D","last_name":"Kaplan","claimtoken":"775f4114cfe81f551b8ddd175ed9c98ff030f2e42996c3bb179c251403a5f71a","first_name":"Eran","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/eran-kaplan-bb1bb171","unsubscribed":false,"is_activeuser":1,"additionalemail":"eran@ioptima.co","claimedemaildate":"2020-09-23 07:23:10.000000","initials":"EK","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yaron Sfadyah","email":"yaron@ioptima.co.il","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPvR1IIKDA","bounced":false,"claimed":0,"founder":0,"urlname":"yaron-sfadyah-2","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgx_LZxQgM","position":"Director of Business Development","last_name":"Sfadyah","claimtoken":"84735ba600c78985aa6fadcb1f8977c5aa2cda295cb0f90bdb5d9093302f5beb","first_name":"Yaron","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yaron-sfadyah-91a399b/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-09-23 07:23:32.000000","initials":"YS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwPi8kYoKDA","fullname":"Ayelet Beazley"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverifydate":"2019-12-19T00:00:00.000Z","crunchbaseid":"ioptima","lastupdator":"Orli Wollner","lastupdator_email":"orlushka@gmail.com","creator":"Tamar Weiss","creator_email":"tamar.e.weiss@gmail.com","createdate":"2014-07-21T00:00:00.000Z","biverification":"Sharon Shapira","sectorverification":"Ayelet Beazley","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkmseOCgw","date":"Sep 2018","amount":"$56M","source":"https://www.calcalistech.com/ctech/articles/0,7340,L-3746606,00.html","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Chengdu Kanghong Pharmaceutical Group","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODk_JO6Cww","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/chengdu-kanghong-pharmaceutical-group","acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":"/company_page/chengdu-kanghong-pharmaceutical-group","acquiredcompany_mna_homepage":null,"style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"/assets/empty-state.svg","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":56000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko9LWCgw","date":"Nov 2015","amount":"$7.2M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Infinity China","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/infinity-china","logokey":null,"tagline":"","urlname":"/investor_page/infinity-china","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCOzOinCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7b96af29-cd17-41cd-a728-88a30fb0d0ab","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Diamond Bio Fund ","type":"Investor","amount":0,"hidden":false,"country":"Taiwan","fullurl":"/investor_page/diamond-bio-fund","logokey":"$RBmMZA7Nq3HCX8yiJgcmSVnzy04oqJK6CPrYOcDyWVNod5FRaUtaaM","tagline":"","urlname":"/investor_page/diamond-bio-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODY5ZHzCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"c9f459e1-3eab-4994-9467-d6c95a243574","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$RBmMZA7Nq3HCX8yiJgcmSVnzy04oqJK6CPrYOcDyWVNod5FRaUtaaM","leadcaption":"","followupcaption":""},{"name":"BIOLIGHT Life Sciences","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/biolight-life-sciences","logokey":"$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","tagline":null,"urlname":"/investor_page/biolight-life-sciences","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OeL444IDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"e5297d18-cc2a-42ba-9236-3c85e7f03b43","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":7200000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/2005","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"IOPtima","logourl":"https://storage.googleapis.com/clean-finder-353810/$H1wowUC40Qeej0FpZ0qzhpPbY8yAVp0DaGt9WiGu5chRMTsjlN6grl","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$H1wowUC40Qeej0FpZ0qzhpPbY8yAVp0DaGt9WiGu5chRMTsjlN6grl","seoabout":"IOPtima is a rapidly growing company focused on developing minimally invasive and innovative surgical ophthalmic devices. Its flagship product, the IOPtima...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Sensing","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LvQ9JYJDA","classificationName":"coretechnology"},{"depth":2,"name":"Laser","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuXyawKDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","TechnologyClassificationModel>Sensing#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LvQ9JYJDA>Laser#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuXyawKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","TechnologyClassificationModel>Sensing#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LvQ9JYJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Sensing#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LvQ9JYJDA|2:>TechnologyClassificationModel>Sensing#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LvQ9JYJDA/Laser#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuXyawKDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Medical Devices","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices","children":[{"title":"Medical Treatment & Therapeutics","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Medical Treatment & Therapeutics"}]},{"title":"Pharma & Medical Biotechnology","key":"0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-1-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]},{"title":"Life Sciences","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Sensing","key":"0-0","path":"TechnologyClassificationModel>Sensing","children":[{"title":"Laser","key":"0-0-0","path":"TechnologyClassificationModel>Sensing>Laser"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Sensing","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LvQ9JYJDA","classificationName":"coretechnology"},{"depth":2,"name":"Laser","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuXyawKDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Medical Devices","Medical Treatment & Therapeutics","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Sensing","Laser"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Providers","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkmseOCgw","date":"Sep 2018","amount":"$56M","source":"https://www.calcalistech.com/ctech/articles/0,7340,L-3746606,00.html","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Chengdu Kanghong Pharmaceutical Group","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODk_JO6Cww","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/chengdu-kanghong-pharmaceutical-group","acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":"/company_page/chengdu-kanghong-pharmaceutical-group","acquiredcompany_mna_homepage":null,"style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"/assets/empty-state.svg","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":56000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko9LWCgw","date":"Nov 2015","amount":"$7.2M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Infinity China","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/infinity-china","logokey":null,"tagline":"","urlname":"/investor_page/infinity-china","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCOzOinCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7b96af29-cd17-41cd-a728-88a30fb0d0ab","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Diamond Bio Fund ","type":"Investor","amount":0,"hidden":false,"country":"Taiwan","fullurl":"/investor_page/diamond-bio-fund","logokey":"$RBmMZA7Nq3HCX8yiJgcmSVnzy04oqJK6CPrYOcDyWVNod5FRaUtaaM","tagline":"","urlname":"/investor_page/diamond-bio-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODY5ZHzCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"c9f459e1-3eab-4994-9467-d6c95a243574","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$RBmMZA7Nq3HCX8yiJgcmSVnzy04oqJK6CPrYOcDyWVNod5FRaUtaaM","leadcaption":"","followupcaption":""},{"name":"BIOLIGHT Life Sciences","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/biolight-life-sciences","logokey":"$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","tagline":null,"urlname":"/investor_page/biolight-life-sciences","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OeL444IDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"e5297d18-cc2a-42ba-9236-3c85e7f03b43","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":7200000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}